Solexa Announces Technical Milestones at the AGBT Conference
News Feb 10, 2006
Solexa, Inc. has announced a number of significant technical advances that highlight the potential of the Solexa Genome Analysis System to transform DNA sequencing and expression profiling.
The presented data provides evidence of the Company’s progress in extending the capabilities of its system to handle a broad range of sequencing applications.
Speaking at the 2006 Advances in Genome Biology and Technology Conference (AGBT), Dr. David Bentley, chief scientist of Solexa, presented data on the Company’s progress in achieving higher raw read accuracy, longer read lengths and paired reads.
He further discussed data that demonstrates the feasibility of using the Solexa Genome Analysis System for resequencing of entire genomes, of candidate and linkage regions and of genes, as well as provided preliminary results from Solexa’s Genome Initiative, the Company’s stated goal to resequence a human genome in 2006.
"The data presented today speaks to the enormous technical progress we have made in recent months, and indicates that we could access a wider segment of the sequencing market and accelerate the adoption rate of the system," stated John West, chief executive officer of Solexa.
"We expect these impressive achievements to enhance the ability of scientists to rapidly and economically resequence genomes using the Solexa Genome Analysis system, and to extend the system’s capabilities to perform true de novo sequencing and other specialized sequencing applications."
The Company also announced its commitment to release data generated from a variety of projects, including Solexa’s Genome Initiative, at regular intervals.
The data, which will include sequence traces as well as aligned reads, will be made available through a browser developed in collaboration with Ensembl.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE